Author:
Hontecillas R,Horne W T,Climent M,Guri A J,Evans C,Zhang Y,Sobral B W,Bassaganya-Riera J
Publisher
Springer Science and Business Media LLC
Subject
Immunology,Immunology and Allergy
Reference41 articles.
1. Hanauer, S.B. & Present, D.H. The state of the art in the management of inflammatory bowel disease. Rev. Gastroenterol. Disord. 3, 81–92 (2003).
2. Bassaganya-Riera, J. et al. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology 127, 777–791 (2004).
3. Desreumaux, P. & Dubuquoy, L. PPARgamma agonists as a new class of effective treatment for ulcerative colitis. Inflamm. Bowel. Dis. 15, 959–960 (2009).
4. Lewis, J.D. et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 134, 688–695 (2008).
5. Marcy, T.R., Britton, M.L. & Blevins, S.M. Second-generation thiazolidinediones and hepatotoxicity. Ann. Pharmacother. 38, 1419–1423 (2004).
Cited by
76 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献